Pharmacokinetics, pharmacodynamics and safety profile of the dual orexin receptor antagonist vornorexant/TS-142 in healthy Japanese participants following single/multiple dosing: Randomized, double-blind, placebo-controlled phase-1 studies.

Kambe, Daiji; Hasegawa, Sayaka; Imadera, Yumiko; Mano, Yoko; Matsushita, Isao; Konno, Yoshihiro; Ogo, Hiroki; Uchimura, Naohisa; Uchiyama, Makoto

Kambe, Daiji; Hasegawa, Sayaka; Imadera, Yumiko; Mano, Yoko; Matsushita, Isao; Konno, Yoshihiro; Ogo, Hiroki; Uchimura, Naohisa; Uchiyama, Makoto.

Affiliation

Kambe D; Development Headquarters, Taisho Pharmaceutical Co., Ltd., Toshima, Tokyo, Japan.
Hasegawa S; Development Headquarters, Taisho Pharmaceutical Co., Ltd., Toshima, Tokyo, Japan.
Imadera Y; Development Headquarters, Taisho Pharmaceutical Co., Ltd., Toshima, Tokyo, Japan.
Mano Y; Development Headquarters, Taisho Pharmaceutical Co., Ltd., Toshima, Tokyo, Japan.
Matsushita I; Development Headquarters, Taisho Pharmaceutical Co., Ltd., Toshima, Tokyo, Japan.
Konno Y; Research Headquarters, Taisho Pharmaceutical Co., Ltd., Kita, Saitama, Japan.
Ogo H; Development Headquarters, Taisho Pharmaceutical Co., Ltd., Toshima, Tokyo, Japan.
Uchimura N; Department of Neuropsychiatry, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Uchiyama M; Department of Psychiatry, Nihon University School of Medicine, Itabashi, Tokyo, Japan.

Basic Clin Pharmacol Toxicol ; 133(5): 576-591, 2023 Nov.

Article in En | MEDLINE | ID: mdl-37563858

Key words

ORN0829; TS-142; clinical trial; orexin receptor antagonist; vornorexant

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Language: En Journal: Basic Clin Pharmacol Toxicol Journal subject: FARMACOLOGIA / TOXICOLOGIA Year: 2023 Document type: Article Affiliation country: Japan Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google